Team

Current board member and advisor for several biotech companies, Gilles Avenard is Medical Doctor and was the co-founder and COO of BioAlliance Pharma SA – ONXEO (NYSE EURONEXT) until 2010. He was notably involved in the development of several innovative medicines through to their official registration on both European and North-American territories. Before that, he worked as Project Director for Hoechst Marion Roussel (Sanofi) and was Medical Director of Bio-Transfusion (LFB).

Professor at University Paris-Saclay (school of Pharmacy), Philippe Billiald is former president of the strategic committee and now scientific consultant at Acticor Biotech. He is an expert in the field of therapeutic and diagnostic antibody engineering. Philippe has published many papers in peer-reviewed scientific journals, books and scientific magazines in his area of expertise. He is also inventor in several international patents and serves in the editorial board of international, peer-reviewed journals: Antibodies, PLoS Negl Trop Dis.

Sophie has over 20 years’ experience in start-ups and mid-size companies within the biotechnology areas. She has a strong expertise in oncology, immunology and virology. Sophie has managed innovative R&D projects from the proof-of-concept to early clinical development. In her previous positions, Sophie was Vice-President Research and Early Clinical Development at PEP-Therapy, responsible for the development of peptide drug candidates in oncology. She was nonclinical R&D Director at InnaVirVax, developing innovative immune-based treatments for infectious diseases. She was Head of translational programs in oncology at Gustave Roussy Cancer Center. During her carrier, Sophie held various positions, at INSERM, CEA, Centre d’Immunologie Pierre Fabre, Bioalliance Pharma (Onxeo) and Stallergenes. Sophie holds a PhD in immunology from Paris VII Denis Diderot university. She is (co-)author of about 20 scientific publications and co-inventor of 9 patents.

Sirine is a medical doctor specialized on vascular surgery and holds a diploma on statistical methodology. After a career on Military Hospital in Tunis, Sirine decided to switch into the medical research field by embracing the career of Medical writer and Medical strategic development officer in 2009. She moved to Roche Tunisia in 2012 where she held the position of Country Medical Director at Roche Tunisia. She has to develop company’s medical strategy, ensure execution of operational plans and setting up clinical trial activities from study selection to publication. Sirine joined B2G Life Sciences since 2016 Clinical development physician and Medical Writer and she was appointed as Medical Director in early 2021. She was responsible for setting up the clinical strategy and develop the company network. She joined Acticor in 2022 as Medical Research Manager.

Alexandra Brochand, PharmD, has a specialization in pharmaceutical biotechnologies and innovative therapies. She worked for 8 years in the French Blood Establishment as Qualified person for advanced therapy medicinal products. She has contributed to the development of the pharmaceutical activity and the associated quality system, including the risk management strategy to be implemented to secure the process and the manufactured products. She joined Acticor Biotech in 2023 as Quality manager and she is involved in the continuous improvement of the activities in collaboration with the different departments of the company.

A scientist by training (engineer), Mohamed has been working in clinical development in the pharmaceutical industry for over 20 years. He has acquired significant experience in CROs (in-house or delegated), then in laboratories both in France (Hoechst Marion Roussel, Sanofi-Synthelabo, Sanofi-Aventis, Lundbeck, Stallergenes Greer) and abroad (Novartis (Basel), Serono (Geneva)). He has also worked as Data Manager, Database Designer, Project leader and Clinical Data Management Manager. He has a strong expertise in data and systems management within clinical trials. He joined Acticor Biotech in mid-2023 as Senior e-Clinical Data and Systems Manager.

Andrea Comenducci, MD, Medical Director at Acticor Biotech. Educated as a General Practitioner, Andrea has more than 25-year experience in the pharmaceutical industry. He assumed various functions from International Project leader and Senior Medical Advisor to Medical Director in medium and large companies. His preferred therapeutic area is the cardiovascular field in which he has vast experience in coronary artery diseases, high blood pressure, heart failure, atherosclerosis acquired in large worldwide clinical trials such as the GUSTO V-TIMI 14 study, STABILITY and SOLID-TIMI 52 studies. In November 2018, Andrea joined Acticor Biotech with the role of Medical Director in order to take up new exciting challenges in acute ischemic stroke, Covid-19 pandemic and pulmonary embolism.

Master’s degree in Bioengineering : Biotechnologies applied to health, Marion Galaup has over 10 years’ experience in the biotechnology areas (Novartis, InnaVirVax and DBV Technologies. She joined Acticor Biotech in 2022 as an analytical project manager.

François Guillet has held positions of great responsibility in companies in a wide variety of sectors, including the high-tech sector, from software publishing at Bea, Oracle and Adobe to the internet, electronics and e-commerce at Monnier Frères. He has contributed to restructuring and turnaround projects in mid-sized companies, with scope extended to Human Resources, Purchasing and Sales Administration. His previous assignments have included managing accounting closures, due diligence and managing multicultural teams internationally, reinforcing his versatility as a financial leader.

Martine Jandrot-Perrus obtained her medical degree in 1977 (University Paris 5) and turned towards medical research. After completing her training in Biochemistry/Enzymology (University Paris Sud), she joined INSERM (the French National Institute on Health and Medical Research) in 1982. She was at the head of the team Molecular and Cellular Mechanisms of Thrombosis from 2003 to 2013. She is now Emeritus Research Director at the Laboratory for Vascular Translational Science (INSERM/University of Paris, Bichat hospital). Her work on haemostasis and thrombosis, and her expertise on platelets and in particular on glycoprotein VI are internationally recognized. Her most notable contributions in this field include the cloning of GPVI, the first description of a subject with a congenital deficit, the identification of new ligands of GPVI and the characterization of its role in the formation of thromboses. She obtained and characterized the antithrombotic properties of the anti-GPVI monoclonal antibody 9O12, precursor of glenzocimab. Author of 11 patents and 171 publications in international journals (h index 40) she received several awards from the Bettencourt-Schueller Foundation (Coup d’Elan 2002), SGAM-ASSET Foundation (Therapeutic Innovation 2007), French Academy of Sciences (2007) and the Esteemed Career Award from the International Society on Thrombosis and Haemostasis in 2019. Since the foundation of Acticor Biotech, she is actively involved in its development as scientific expert.

Marilyn has over 20 years’ experience in pharmaceutical development and global clinical project management especially in oncology, virology and Intensive care unit. She previously assumed the functions of International Clinical Project Manager in pharmaceutical companies and CRO (Clinical Research Organization). Before that, she spent the beginning of her career in marketing and participated in the launching of several innovative products in oncology for Chiron and Aventis.

Following an STMG baccalaureate, Antoine turned to the world of communication. He is preparing a BTS in communication within Acticor Biotech. He joined the company as a communication and IT assistant in September 2020.

Dedicated Clinical Trial Assistant (CTA) with different project experiences within CRO (I3 Life Science, Hays Pharma, Kelly Outsourcing Consultant Group) and Pharmaceutical Industries (Pfizer, Roche, Chiesi and Lilly) from Project Launching to Close-Out (through different processes of Site Start-Up, TMF, e-TMF Archiving, Budget Management, Study follow-up, etc and Close-out).

Sandra has more than 20 years of administrative and commercial management experience in various jobs in the pharmaceutical industry, first with Alergovet on the national market and then with Stallergenes on the international market. This signifiant experience allows her today to offer her services as an independent office manager to small and medium-sized companies and startups. She has worked with Acticor Biotech since October 2022 on office manager and cross-functional project management missions

Adeline Meilhoc, DPsy, is directing the global clinical trials in bringing her expertise to ACTICOR Biotech in team management and strategic & operational study structuration. She has spent her career in the clinical Drug Development in pharma and contract research organization entities, both as VP Medical Affairs & Clinical Operations and as VP Business Development. She has built several departments in the medical and clinical trial feasibility, in study start-up and in medical imaging as well as commercial and marketing development. Specializing in building business relationships, she has spent the last few years developing Marketing & Sales strategies for various eClinical tools to Healthcare Professionals and Medical Device companies, in addition to her own businesses. Her strong expertise in Real World Evidence and in the operational aspect of market access has broaden her vision of drug development and launch. She is clinical psychologist - ICP - EPP of Paris, specialized in the field of Health & Society.

Stéphanie PAUL, Clinical Operations Trainer, at Acticor Biotech, background of study research nurse. She has more than 15 years of experience in a clinical research center in CHRU from Brest. She assumed various functions from study coordinator in different therapeutic domains: respiratory, thromboembolic diseases, vascularitis and neurological area. She supervised both French and international trials, and realized all the technical care, in respect of GCP. She comes from hospital so she could be a veritable resource for the training staff.

Dr Plétan is an expert in clinical development within the pharmaceutical industry. He previously held leadership positions at Roche, Pfizer, Sanofi and Pierre Fabre. Before joining Acticor Biotech, Dr Plétan served as head of the Medical Division and was a board member of the Foundation at Roche France and member of the Global Medical Affairs Committee at Hoffman La Roche Ltd (Switzerland). Prior to these activities, he was also vice-president, head of Medical and Scientific Division and board member of the Foundation at Pfizer.

Anitha Pobbati an accomplished healthcare professional , pursued Msc in Global business management from Rennes school of Business and Bsc in Advanced Nursing. She is skilled in management of clinical studies and Business acumen. Added experience in Marketing, communications and Management. She possess meticulous clinical management adept and the development & implementation of clinical practices. She is passionate to work and develop the Health services to provide better health systems for the wellness of patients. She joined Acticor Biotech in 2022 as Clinical Operations Trainer.

Anouar has more than 20 years of experience working in the pharmaceutical industry. He began his career at Gustave Roussy Institute, then ICON Clinical research and Nanobiotix, holding various positions and acting as “Global Clinical Project Manager” and “Associate Director Clinical Operations” afterwards.

Elie has 10 years of experience in major companies and public-private bodies within the biotechnology area. Committed to bring breakthrough innovations to patient as fast as possible, he has a broad expertise in several therapeutic areas. Elie has managed strategic alliances of innovative R&D projects from the proof-of-concept to clinical development. During his carrier, he held various positions, at Curie Institute, Total New energy, Roche, and Conectus. Elie holds a Master in Molecular and Cellular Biology from Ecole Normale Supérieure de Lyon, and a PhD in Molecular Biology done within Pasteur Institute (Paris). He joined Acticor Biotech in 2021 as Head of Global Project Coordination.